Search results for "Triggering"

showing 10 items of 25 documents

Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia

2018

IF 7.607; International audience; Innate lymphoid cells (ILCs) have been characterized as innate immune cells capable to modulate the immune response in the mucosae. Human ILCs have been rarely described in secondary lymphoid organs except in tonsils. Moreover, their function and phenotype in human secondary lymphoid organs during autoimmune diseases have never been studied. We took advantage of splenectomy as a treatment of immune thrombocytopenia (ITP) to describe and compare splenic ILC from 18 ITP patients to 11 controls. We first confirmed that ILC3 represented the most abundant ILC subset in human non-inflamed spleens, accounting for 90% of total ILC, and that they were mostly constit…

0301 basic medicineAdultMalemedicine.medical_treatmentImmunologySplenectomyGene ExpressionSpleenInnate lymphoid cells[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInterferon-gamma0302 clinical medicineImmune systemhemic and lymphatic diseasesmedicineImmunology and AllergyHumansLymphocyte CountLymphocytesskin and connective tissue diseasesAutoimmune diseasePurpura Thrombocytopenic IdiopathicInnate immune systemNatural Cytotoxicity Triggering Receptor 2business.industryMacrophagesInnate lymphoid cellInterleukin-2 Receptor alpha SubunitGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationMiddle Agedmedicine.diseasePathophysiologyImmunity Innate3. Good healthImmune thrombocytopenia030104 developmental biologymedicine.anatomical_structureLymphatic systemCase-Control StudiesImmunologySplenectomyFemalebusinessSpleen030215 immunology
researchProduct

The Stalk Domain of NKp30 Contributes to Ligand Binding and Signaling of a Preassembled NKp30-CD3ζ Complex

2016

The natural cytotoxicity receptor (NCR) NKp30 (CD337) is a key player for NK cell immunosurveillance of infections and cancer. The molecular details of ligand recognition and its connection to CD3ζ signaling remain unsolved. Here, we show that the stalk domain (129KEHPQLGAGTVLLLR143) of NKp30 is very sensitive to sequence alterations, as mutations lead to impaired ligand binding and/or signaling capacity. Surprisingly, the stalk domains of NKp30 and NKp46, another NCR employing CD3ζ for signaling, were not exchangeable without drastic deficiencies in folding, plasma membrane targeting, and/or ligand-induced receptor signaling. Further mutational studies, N-glycosylation mapping, and plasma …

0301 basic medicineCell signalingCD3 ComplexImmunologyProtein domainBiologyCD3 ComplexBiochemistryCell membraneMice03 medical and health sciencesProtein DomainsCell surface receptormedicineAnimalsHumansMolecular BiologyNatural Cytotoxicity Triggering Receptor 3Natural Cytotoxicity Triggering Receptor 1Cell MembraneCell BiologyLigand (biochemistry)Cell biology030104 developmental biologymedicine.anatomical_structureMembrane proteinBiochemistrySignal transductionHeLa CellsSignal TransductionJournal of Biological Chemistry
researchProduct

A murine intestinal intraepithelial NKp46-negative innate lymphoid cell population characterized by group 1 properties

2017

The Ly49E receptor is preferentially expressed on murine innate-like lymphocytes, such as epidermal Vγ3 T cells, intestinal intraepithelial CD8αα(+) T lymphocytes, and CD49a(+) liver natural killer (NK) cells. As the latter have recently been shown to be distinct from conventional NK cells and have innate lymphoid cell type 1 (ILC1) properties, we investigated Ly49E expression on intestinal ILC populations. Here, we show that Ly49E expression is very low on known ILC populations, but it can be used to define a previously unrecognized intraepithelial innate lymphoid population. This Ly49E-positive population is negative for NKp46 and CD8αα, expresses CD49a and CD103, and requires T-bet expre…

0301 basic medicineCytotoxicity ImmunologicSUBSETSROR-GAMMA-TLYMPHOCYTESILC1TranscriptomeMice0302 clinical medicineInterferonNKp46-negativeMedicine and Health SciencesAntigens LyInterferon gammaLymphocytesIFN-γlcsh:QH301-705.5education.field_of_studyintestinalIFN-GAMMAInnate lymphoid cellNATURAL-KILLERIntestinesKiller Cells NaturalPhenotypeDIFFERENTIATIONSignal transductionNK Cell Lectin-Like Receptor Subfamily Amedicine.drugSignal TransductionintraepithelialEXPRESSIONPopulationNKP46(+) CELLSBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesInterferon-gammaImmunityAntigens CDmedicineAnimalseducationCell ShapeNatural Cytotoxicity Triggering Receptor 1INHIBITORY RECEPTORSBiology and Life SciencesEpithelial CellsMolecular biologyImmunity InnateNK-CELLS030104 developmental biologyNatural Cytotoxicity Triggering Receptor 1lcsh:Biology (General)ImmunologyTranscriptomeLy49E030215 immunologyTranscription Factors
researchProduct

NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer

2019

γδ T cells account for a large fraction of human intestinal intraepithelial lymphocytes (IELs) endowed with potent anti-tumor activities. However, little is known about their origin, phenotype and clinical relevance in colorectal cancer (CRC). To determine γδ IEL gut-specificity, homing and functions, γδ T cells were purified from human healthy blood, lymph nodes, liver, skin, intestine either disease-free or affected by CRC or generated from thymic precursors. The constitutive expression of NKp46 specifically identifies a new subset of cytotoxic Vδ1 T cells representing the largest fraction of gut-resident IELs. The ontogeny and gut-tropism of NKp46pos/Vδ1 IELs depends both on distinctive …

0301 basic medicineMaleColorectal cancerImmunotherapy AdoptiveMice0302 clinical medicineSex Hormone-Binding GlobulinCytotoxic T cellAntigens LyIntestinal MucosaIntraepithelial LymphocytesInnate immunityAged 80 and overGastroenterologyAge FactorsReceptors Antigen T-Cell gamma-deltaGeneral MedicineMiddle AgedPhenotypemedicine.anatomical_structure030220 oncology & carcinogenesisDisease ProgressionFemaleColorectal NeoplasmsResearch ArticleAdultColonT cellImmunologyT cellsBiologydigestive systemColorectal cancer; Gastroenterology; Immunology; Innate immunity; T cells03 medical and health sciencesYoung AdultIleummedicineAnimalsHumansAgedNeoplasm StagingTumor microenvironmentInnate immune systemNatural Cytotoxicity Triggering Receptor 1medicine.diseaseColorectal cancer030104 developmental biologyCancer researchIntraepithelial lymphocyteHoming (hematopoietic)T-Lymphocytes Cytotoxic
researchProduct

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

2018

Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-common hematologic malignancy. Despite advances in therapy, MM remains largely incurable. Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, which is highly expressed on myeloma cells, and the antibody is approved for the treatment of relapsed and/or refractory (RR) MM in combination with lenalidomide and dexamethasone. Elotuzumab can stimulate robust antibody-dependent cellular cytotoxicity (ADCC) through engaging with FcγRIIIA (CD16) on NK cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages. Interestingly, SLAMF7 is also expressed on cytolytic NK cells, which also expr…

0301 basic medicineReviewNK cellsLymphocyte ActivationDexamethasoneMice0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyElotuzumabLenalidomideMultiple myelomaAntibody-dependent cell-mediated cytotoxicityBortezomibSLAMF7ADCPPlasma cell neoplasmelotuzumab3. Good healthmultiple myelomaKiller Cells Naturalmedicine.anatomical_structureNK Cell Lectin-Like Receptor Subfamily K030220 oncology & carcinogenesisSLAMF7ADCCmedicine.druglcsh:Immunologic diseases. AllergyImmunologyPlasma CellsAntineoplastic AgentsmacrophageAntibodies Monoclonal HumanizedGPI-Linked Proteins03 medical and health sciencesPhagocytosisSignaling Lymphocytic Activation Molecule FamilymedicineBiomarkers TumorAnimalsHumansbusiness.industryNatural Cytotoxicity Triggering Receptor 1MacrophagesReceptors IgGNKG2Dmedicine.disease030104 developmental biologyCancer researchBone marrowbusinesslcsh:RC581-607Transcription FactorsFrontiers in Immunology
researchProduct

Dynamic Triggering of Mud Volcano Eruptions During the 2016–2017 Central Italy Seismic Sequence

2017

©2017. American Geophysical Union. All Rights Reserved. On 24 August 2016 a seismic event (Mw6.0) was the first of the long Central Italy sequence (ongoing at the end of 2017) of medium-to-high magnitude earthquakes, with nine Mw≥5 up to October 2017, and with about 74.000 seismic events registered after 1 year. The largest was the Mw6.5 30 October 2016 event near Norcia. After the major seismic events, 17 mud volcanoes erupted around Monteleone di Fermo village (Marche region). Mud volcano eruptions generally occurred a few hours to a few days after the main earthquakes, suggesting a seismic triggering. We analyzed the peak ground velocities and dynamic stresses during the three largest ea…

2016-2017 seismic sequenceseismic triggeringmud volcano eruptionCentral ItalyGeochemistryGeophysicsremote triggeringmud volcanoestatic stressdynamic stressGeologyearthquakes
researchProduct

Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome.

2012

OBJECTIVES: In chronic inflammatory disorders, interleukin (IL)-22 may act either as a protective or as a pro-inflammatory cytokine. At mucosal sites, IL-22 is mainly produced by CD4(+) T cells and by a subset of mucosal natural killer (NK) cells expressing the receptor NKp44 (NKp44(+) NK cells). The aim of this study was to investigate the IL-22 expression in the salivary glands of patients with primary Sjögren's syndrome (pSS). METHODS: Minor salivary gland biopsies were obtained from 19 patients with pSS and 16 with non-specific chronic sialoadenitis. Quantitative gene expression analysis by TaqMan real-time PCR and immunohistochemistry for IL-17, IL-22, IL-23 and STAT3 (signal transduce…

AdultCD4-Positive T-LymphocytesMaleSTAT3 Transcription FactorAnkylosing Spondylitis IL-22 NKp44NK cells intestinal inflammationmedicine.medical_treatmentImmunologySalivary Glands MinorInterleukin-23General Biochemistry Genetics and Molecular BiologySialadenitisInterleukin 22PathogenesisRheumatologyintestinal inflammationIL-22Immunology and AllergyMedicineHumansRNA MessengerSTAT3ReceptorAgedAnkylosing SpondylitibiologySalivary glandNatural Cytotoxicity Triggering Receptor 2business.industryReverse Transcriptase Polymerase Chain ReactionInterleukinsInterleukin-17InterleukinMiddle AgedNKp44NK cellKiller Cells NaturalSettore MED/16 - ReumatologiaCytokinemedicine.anatomical_structureSjogren's SyndromeCase-Control StudiesImmunologybiology.proteinImmunohistochemistryFemalebusinessAnnals of the rheumatic diseases
researchProduct

Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients w…

2015

Background The aim of the study was to better characterise the immunological origin and the behaviour of interleukin (IL)-23-responsive innate lymphoid cells (ILCs) in the gut, synovial fluid (SF) and bone marrow (BM) of patients with ankylosing spondylitis (AS).Methods ILC1, ILC2 and ILC3 cells were determined and characterised by confocal microscopy and flow cytometry in ileal and BM biopsies, in peripheral blood (PB) and SF mononuclear cells obtained from patients with AS and controls. Mucosal vascular addressin cell adhesion molecule 1 (MADCAM-1), IL-7, IL-15 and aggregates of lymphoid tissue inducer cells (LTi) were evaluated by immunohistochemistry. The in vitro ability of epithelial …

AdultMalePathologymedicine.medical_specialtyAdolescentImmunologyHigh endothelial venulesImmunoglobulinsPeripheral blood mononuclear cellGeneral Biochemistry Genetics and Molecular BiologyInterleukin 22Young AdultMucoproteinsAnkylosing Spondylitis; Cytokines; InflammationRheumatologyBone MarrowIleumSynovial FluidAddressinImmunology and AllergyMedicineSynovial fluidHumansSpondylitis AnkylosingLymphocytesIntestinal MucosaCytokineAgedInterleukin-15InflammationMicroscopy ConfocalAnkylosing SpondylitibiologyNatural Cytotoxicity Triggering Receptor 2business.industryInterleukin-7InterleukinsInnate lymphoid cellInterleukin-17Middle AgedSettore MED/16 - Reumatologiamedicine.anatomical_structureLymphatic systemCase-Control Studiesbiology.proteinFemaleBone marrowbusinessCell Adhesion Molecules
researchProduct

Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis

2012

Objective The intestinal inflammation observed in patients with ankylosing spondylitis (AS) is characterized by an overexpression of interleukin-23 (IL-23). IL-23 is known to regulate IL-22 production through lamina propria NKp44+ natural killer (NK) cells, which are thought to be involved in protective mucosal mechanisms. This study was undertaken to evaluate the frequency of NKp44+ NK cells and the expression of IL-22 in the ileum of AS patients. Methods Tissue NKp44+ NK cells, NKp46+ NK cells, and IL-22–producing cells were analyzed by flow cytometry. Quantitative gene expression analysis of IL-22, IL-23, IL-17, STAT-3, and mucin 1 (MUC-1) was performed by reverse transcriptase–polymeras…

AdultMaleSTAT3 Transcription FactorImmunologyIleumBiologyInterleukin-23Peripheral blood mononuclear cellFlow cytometryAnkylosing spondylitis IL-22 intestinal inflammation intestinal inflammationInterleukin 22Interleukin 21RheumatologyIleumintestinal inflammationIL-22medicineHumansImmunology and AllergySpondylitis AnkylosingPharmacology (medical)Intestinal MucosaInflammationLamina propriaNatural Cytotoxicity Triggering Receptor 2medicine.diagnostic_testInterleukinsMucin-1MucinMiddle AgedKiller Cells NaturalAnkylosing spondylitimedicine.anatomical_structureImmunologyImmunohistochemistryFemaleArthritis & Rheumatism
researchProduct

Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1 in patients with IBD do not correlate with intestinal TREM-1 mRNA e…

2012

BACKGROUND AIMS Triggering receptor expressed on myeloid cells 1 (TREM 1) is a potent amplifier of pro inflammatory responses. We have previously demonstrated a substantial increase in TREM 1 expressing macrophages in the inflamed intestinal mucosa of patients with inflammatory bowel diseases (IBD). TREM 1 is also produced as a soluble receptor (sTREM 1). Here we aimed to determine whether serum sTREM 1 could be used as a surrogate marker of disease activity in patients with IBD. METHODS Intestinal biopsies and concurrently collected sera from patients with Crohn's disease (CD) and Ulcerative colitis (UC) enrolled in the Swiss IBD cohort study were analyzed for intestinal TREM 1 mRNA and se…

AdultMalemedicine.medical_specialtyMyeloidColonGastroenterologyInflammatory bowel diseaseEndoscopy GastrointestinalStatistics Nonparametric03 medical and health sciencesMice0302 clinical medicineIntestinal mucosaCrohn DiseaseIleumInternal medicinemedicineAnimalsHumansRNA MessengerColitisReceptors ImmunologicReceptor030304 developmental biology0303 health sciencesCrohn's diseaseMessenger RNAMembrane Glycoproteinsbusiness.industryGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisAdoptive Transferdigestive system diseasesTriggering Receptor Expressed on Myeloid Cells-13. Good healthmedicine.anatomical_structureROC CurveArea Under CurveImmunologyColitis UlcerativeFemalebusinessBiomarkers030215 immunologyJournal of Crohn's & colitis
researchProduct